Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

Open access
Lyttle, Mark D, Rainford, Naomi E A, Gamble, Carrol, Messahel, Shrouk, Humphreys, Amy, Hickey, Helen, Woolfall, Kerry, Roper, Louise, Noblet, Joanne, Lee, Elizabeth D, Potter, Sarah, Tate, Paul, Iyer, Anand, Evans, Vicki, Appleton, Richard E, Pereira, Matthew, Hardwick, Susie, Messahel, Shrouk, Noblet, Joanne, Lee, Elizabeth D, Greenwood-Bibby, Rachel, Buchanan, Mark, Lewis, Lucy, Hughes, Sharon, Hartshorn, Stuart, Rogers, Louise, Hopkins, Juliet, Lyttle, Mark D, Fernandez, Daphin, Potter, Sarah, Lavigne-Smith, Holly R, Moulsdale, Phoebe, Smith, Alice, Bingham, Tracey, Ross, James, Ramsey, Natasha, Hacking, Jo, Mullen, Niall, Corrigan, Paul P, Prudhoe, Sarah, Faza, Hani, Robinson, Gisela, Sunley, Rachel C, Smith, Coral J, Unsworth, Vanessa, Criddle, John, Laque, Martin, Sheedy, Alyce B, Anderson, Mark, Bell, Kathryn, Devine, Kirsty, Scott, Alex, Kumar, Ramesh, Armstrong, Sonia, Sutherland, Emer, Cantle, Fleur, Helyer, Sinead, Riozzi, Paul, Cotton, Hannah, Downes, Alice J, Mollard, Helen, Roland, Damian, Hay, Felix, Gough, Christopher, Finucane, Sonya, Bevan, Catherine, Ramsay, Rebecca, Walton, Emily, Maney, Julie-Ann, Dalzell, Elizabeth, Millar, Muriel, Howells, Rachel J, Appelboam, Andy, Mackle, Daisy, Small, Jennie, Neil, Ashleigh, Choudhery, Vince, MacLeod, Stewart, Browning, Jen, O'Neill, Thomas, Grahamslaw, Julia, Parikh, Ami, Skene, Imogen, Thomas, Rhys, Potier de la Morandiere, Katherine, Wilson, Jill L, Danziger, Donna, Burke, Derek, Ramlakhan, Shammi, Evans, Jayne, Morcombe, Julie, Gormley, Stuart, Barling, Jason M, Cathie, Katrina, Bayreuther, Jane, Ensom, Ruth, Iqbal, Yasser, Rounding, Sarah, Mulligan, Joanne, Bell, Claire, McLellan, Shona, Leighton, Shona, Sajjanhar, Tina, Nyirenda, Maggie, Crome, Laura, Williamson, Neil, Alcock, Anastasia, Edwards, Sara, Morgan, Jeff, Powell, Colin VE, Ramesh, Chaniyil A, Kamal-Uddin, Solomon, Linney, Mike, Vamvakiti, Katia, Floyd, Sharon, Hobden, Gill·2019·The Lancet

Abstract

BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus. METHODS: This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary outcome was time from randomisation to cessation of convulsive status epilepticus, analysed in the modified intention-to-treat population (excluding those who did not require second-line treatment after randomisation and those who did not provide consent). This trial is registered with ISRCTN, number ISRCTN22567894. FINDINGS: Between July 17, 2015, and April 7, 2018, 1432 patients were assessed for eligibility. After exclusion of ineligible patients, 404 patients were randomly assigned. After exclusion of those who did not require second-line treatment and those who did not consent, 286 randomised participants were treated and had available data: 152 allocated to levetiracetam, and 134 to phenytoin. Convulsive status epilepticus was terminated in 106 (70%) children in the levetiracetam group and in 86 (64%) in the phenytoin group. Median time from randomisation to cessation of convulsive status epilepticus was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min (24 to not assessable) in the phenytoin group (hazard ratio 1·20, 95% CI 0·91-1·60; p=0·20). One participant who received levetiracetam followed by phenytoin died as a result of catastrophic cerebral oedema unrelated to either treatment. One participant who received phenytoin had serious adverse reactions related to study treatment (hypotension considered to be immediately life-threatening [a serious adverse reaction] and increased focal seizures and decreased consciousness considered to be medically significant [a suspected unexpected serious adverse reaction]). INTERPRETATION: Although levetiracetam was not significantly superior to phenytoin, the results, together with previously reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status epilepticus. FUNDING: National Institute for Health Research Health Technology Assessment programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)30724-x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 253

Metadata

Authors
Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., Lee, E. D., Greenwood-Bibby, R., Buchanan, M., Lewis, L., Hughes, S., Hartshorn, S., Rogers, L., Hopkins, J., Lyttle, M. D., Fernandez, D., Potter, S., Lavigne-Smith, H. R., Moulsdale, P., Smith, A., Bingham, T., Ross, J., Ramsey, N., Hacking, J., Mullen, N., Corrigan, P. P., Prudhoe, S., Faza, H., Robinson, G., Sunley, R. C., Smith, C. J., Unsworth, V., Criddle, J., Laque, M., Sheedy, A. B., Anderson, M., Bell, K., Devine, K., Scott, A., Kumar, R., Armstrong, S., Sutherland, E., Cantle, F., Helyer, S., Riozzi, P., Cotton, H., Downes, A. J., Mollard, H., Roland, D., Hay, F., Gough, C., Finucane, S., Bevan, C., Ramsay, R., Walton, E., Maney, J.-A., Dalzell, E., Millar, M., Howells, R. J., Appelboam, A., Mackle, D., Small, J., Neil, A., Choudhery, V., MacLeod, S., Browning, J., O'Neill, T., Grahamslaw, J., Parikh, A., Skene, I., Thomas, R., Potier de la Morandiere, K., Wilson, J. L., Danziger, D., Burke, D., Ramlakhan, S., Evans, J., Morcombe, J., Gormley, S., Barling, J. M., Cathie, K., Bayreuther, J., Ensom, R., Iqbal, Y., Rounding, S., Mulligan, J., Bell, C., McLellan, S., Leighton, S., Sajjanhar, T., Nyirenda, M., Crome, L., Williamson, N., Alcock, A., Edwards, S., Morgan, J., Powell, C. V., Ramesh, C. A., Kamal-Uddin, S., Linney, M., Vamvakiti, K., Floyd, S., & Hobden, G.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-05
Volume
393
Issue
10186
Pages
2125-2134
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2937512232
Cited by
253
References
19
FWCI
24.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)30724-x
The paper
Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., . . . Hobden, G. (2019). Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)30724-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.